The promise and perils of CNS drug delivery: a video debate.
Neurodegenerative and infectious disorders related to host genetics, aging, and environment are rapidly increasing. Drugs, vaccines, or regenerative proteins offer "real" possibilities for positively affecting disease outcomes but are limited by access across the blood-brain barrier. New developments in nanomedicine and cell based drug delivery are becoming available. These discoveries can lead to improved neurological disease outcomes. Such obstacles include the toxicities inherent in the delivery systems de novo such as immuno- and neurological dysfunctions and perturbations of blood-brain barrier function. This debate by leading experts in the field highlights the promise and perils of CNS drug delivery. Click on Supplemental HTML to watch the streaming video.
Gendelman
Howard E
HE
Center for Neurovirology and Neurodegenerative Disorders, Department of Pharmacology, University of Nebraska Medical Center, 985880 Nebraska Medical Center, Omaha, NE 68198-5880, USA, hegendel@unmc.edu
Kabanov
Alexander
A
Linder
James
J
D001812:Blood-Brain Barrier; D002491:Central Nervous System Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002493:Central Nervous System Diseases / Q000188:drug therapy; D004333:Drug Administration Routes; D016503:Drug Delivery Systems / Q000009:adverse effects; D006801:Humans
D002491:Central Nervous System Agents